Relja Popovic

9.5k citations

41 papers · 3.0k indexed · 2 hit papers · h-index 23

Impact in

Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
Molecular Biology top 5%
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- Cancer-related gene regulation
- Genomics and Chromatin Dynamics

Papers in

Hematology 23
- Acute Myeloid Leukemia Research 15
- Multiple Myeloma Research and Treatments 10
Genetics 6
- Chronic Lymphocytic Leukemia Research 6

Co-authors: Jonathan D. Licht Nancy J. Zeleznik‐Le Eva Martínez-García Christine Will Neil L. Kelleher Brenda Chyla Tu Xu Andrew H. Wei
Journals: Blood (12 papers)Proceedings of the National Academy of Sciences (3 papers)Cancer Research (3 papers)Cell Reports (2 papers)Oncogene (2 papers)
Partner nations: United States Australia Germany

In The Last Decade

Relja Popovic

38 papers receiving 2.9k citations

Hit Papers

align trajectories log scale

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study 2019 · 456 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Journal of Clinical Oncology
2018 The Lancet Oncology

Peers

Countries citing papers authored by Relja Popovic

Since Specialization

Citations

This map shows the geographic impact of Relja Popovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Relja Popovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Relja Popovic more than expected).

Fields of papers citing papers by Relja Popovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Relja Popovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Relja Popovic. The network helps show where Relja Popovic may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Relja Popovic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Relja Popovic Line = papers co-authored together Relja Popovic links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Lipid Composition Alters Ferroptosis Sensitivity Cancer Research ·T. Kristoffer, 张敏聪, Justin P. Ingram, Seferu Tadesse, Julie J. Purkal, 眞人村田, 蒋素, S. Kubis, 幸二前田, А. В. Земсков, Jitra Wongwiwattanaono, Sarah Kongpachith, Darren C. Phillips, Scott J. Dixon, Relja Popovic	2025	0
2	Data from Lipid Composition Alters Ferroptosis Sensitivity T. Kristoffer, 张敏聪, Justin P. Ingram, Seferu Tadesse, Julie J. Purkal, 眞人村田, 蒋素, S. Kubis, 幸二前田, А. В. Земсков, Jitra Wongwiwattanaono, Sarah Kongpachith, Darren C. Phillips, Scott J. Dixon, Relja Popovic	2025	0
3	A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia Cancer ·Gautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, David A. Rizzieri, Thomas Prébet, Christopher S. Chen, Relja Popovic, Dimple Modi, Nina Heinemann, Johannes Wolff, Brian A. Jonas	2021	51
4	5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis Clinical Cancer Research ·Sha Jin, Dan Cojocari, Julie J. Purkal, Relja Popovic, Nari Talaty, Xiao Yu, Larry R. Solomon, Erwin R. Boghaert, Joel Johansson, Darren C. Phillips	2020	126
5	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study Journal of Clinical Oncology ·Andrew H. Wei, Stephen A. Strickland, Jing-Zhou Hou, Walter Fiedler, Tara L. Lin, Roland B. Walter, Anoop Enjeti, Ing Soo Tiong, Michael R. Savona, Sang‐Min Lee, Brenda Chyla, Relja Popovic, Ahmed Hamed Salem, Suresh Agarwal, Tu Xu, Kaffa Fakouhi, Rod Humerickhouse, Mikaela Isacson, John Hayslip, Gail J. Roboz Hit paper breakdown →	2019	456
6	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study The Lancet Oncology ·Courtney D. DiNardo, Keith W. Pratz, Anthony Letai, Brian A. Jonas, Andrew H. Wei, Michael J. Thirman, Martha Arellano, Mark G. Frattini, Hagop M. Kantarjian, Relja Popovic, Brenda Chyla, Tu Xu, Martin Dunbar, Suresh Agarwal, Rod Humerickhouse, Mack Mabry, Jalaja Potluri, Marina Konopleva, Daniel A. Pollyea Hit paper breakdown →	2018	498
7	5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis Blood ·Dan Cojocari, Sha Jin, Julie J. Purkal, Relja Popovic, Nari Talaty, Xiao Yu, Larry R. Solomon, Erwin R. Boghaert, Joel Johansson, Darren C. Phillips	2018	1
8	UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition Cell Reports ·Teresa Ezponda, Daphné Dupéré-Richer, Christine Will, Eliza C. Small, Nobish Varghese, Stacy Sue Rosello, Behnam Nabet, Relja Popovic, Jon A. Oyer, Marinka Bulic, Yupeng Zheng, Xiaoxiao Huang, Mrinal Y. Shah, Sayantan Maji, Alberto Riva, Hakan Oğuz Arı, Giovanni Tonon, Neil L. Kelleher, Jonathan J. Keats, Jonathan D. Licht	2017	92
9	MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents Oncogene ·Maitri Shah, Eva Martínez-García, Jude M. Phillip, Allison B Chambliss, Relja Popovic, Teresa Ezponda, Eliza C. Small, Christine Will, 攻宮下, Paola Neri, Nizar J. Bahlis, Denis Wirtz, Jonathan D. Licht	2016	67
10	Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation Leukemia & lymphoma ·Zheng Zhou, Juehua Gao, Relja Popovic, Kristy Wolniak, Vamsi Parimi, Jane N. Winter, Jonathan D. Licht, Evelia Arévalo González	2015	27
11	Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape Cell Reports ·Behnam Nabet, Pilib Ó Broin, Jaime M. Reyes, Fitri Yudiati, Charles Y. Lin, Christine Will, Relja Popovic, Teresa Ezponda, James E. Bradner, Jong-Sam Baik, Jonathan D. Licht	2015	33
12	Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation PLoS Genetics ·Relja Popovic, Eva Martínez-García, Ευγενία Γιαννοπούλου, Quanwei Zhang, Qingyang Zhang, Teresa Ezponda, Mrinal Y. Shah, Yupeng Zheng, Christine Will, Eliza C. Small, Youjia Hua, Marinka Bulic, Yanwen Jiang, Matteo Carrara, Raffaele Calogero, William L. Kath, Neil L. Kelleher, Mtt Nguyen, Olivier Elemento, Jonathan D. Licht	2014	180
13	MMSET dysregulates gene expression in myeloma through global and focal changes in H3K36 and H3K27 methylation Epigenetics & Chromatin ·Relja Popovic, Eva Martínez-García, Quanwei Zhang, Teresa Ezponda, Mrinal Y. Shah, 乔国海, Yanwen Jiang, Christine Will, Eliza C. Small, Marinka Bulic, Olivier Elemento, Neil L. Kelleher, William L. Kath, Bhatia Aakansha, Jonathan D. Licht	2013	3
14	The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial–mesenchymal transition and invasive properties of prostate cancer Oncogene ·Teresa Ezponda, Relja Popovic, Maitri Shah, Eva Martínez-García, Yupeng Zheng, A. S. Vasilyev, Christine Will, Antonino Neri, Neil L. Kelleher, Jian Yu, Jonathan D. Licht	2012	130
15	MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC Leukemia ·A. S. Vasilyev, Teresa Ezponda, Alper Yenigun, Christine Will, Eva Martínez-García, Relja Popovic, Venkatesha Basrur, Kojo S.J. Elenitoba‐Johnson, Jonathan D. Licht	2012	70
16	Structure of the MLL CXXC domain–DNA complex and its functional role in MLL-AF9 leukemia Nature Structural & Molecular Biology ·Tomasz Cierpicki, Rylee Shannon McGuire, Jolanta Grembecka, Stephen M. Lukasik, Relja Popovic, G. Pigato, David Shultis, Nancy J. Zeleznik‐Le, John H. Bushweller	2009	144
17	Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization Blood ·Relja Popovic, K.majdoub, Chinavenmeni S. Velu, Aditya Chaubey, Jiwang Zhang, Nicholas J. Achille, Frank Erfurth, Césas Roberto, Jun Lü, H. Leighton Grimes, Jianjun Chen, Janet D. Rowley, Nancy J. Zeleznik‐Le	2009	171
18	Transcriptional complexity of the HOXA9 locus Blood Cells Molecules and Diseases ·Relja Popovic, Frank Erfurth, Nancy J. Zeleznik‐Le	2007	20
19	Bromodomain and Histone Acetyltransferase Domain Specificities Control Mixed Lineage Leukemia Phenotype Cancer Research ·Donna A. Santillan, Catherine Theisler, Marta Gretchman, Relja Popovic, ایمن عبد القادر, Ming‐Ming Zhou, Serhan Alkan, Nancy J. Zeleznik‐Le	2006	21
20	MLL: How complex does it get? Journal of Cellular Biochemistry ·Relja Popovic, Nancy J. Zeleznik‐Le	2005	71

About Relja Popovic

Relja Popovic is a scholar working on Hematology, Genetics, Molecular Biology, Cancer Research and Public Health, Environmental and Occupational Health, having authored 41 papers that have together received 3.0k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (15 papers), Epigenetics and DNA Methylation (14 papers), Histone Deacetylase Inhibitors Research (12 papers), Protein Degradation and Inhibitors (12 papers), Multiple Myeloma Research and Treatments (10 papers), Chronic Lymphocytic Leukemia Research (6 papers), Cancer-related gene regulation (6 papers) and Genomics and Chromatin Dynamics (6 papers). The work is most often cited by research in Hematology (1.5k citations), Molecular Biology (2.3k citations), Genetics (332 citations), Cancer Research (384 citations) and Oncology (403 citations). Relja Popovic has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Jonathan D. Licht, Nancy J. Zeleznik‐Le, Eva Martínez-García, Christine Will, Neil L. Kelleher, Brenda Chyla, Tu Xu, Andrew H. Wei, Suresh Agarwal and Rod Humerickhouse. Their work appears in journals such as Blood, Proceedings of the National Academy of Sciences, Cancer Research, Cell Reports and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact